Lauren Hayslette, PA
Physician Assistant · Lansing, MINPI 1124619523
Payments from drug & device makers
Across 480 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Grifols USA, LLC$1K
- Boehringer Ingelheim$1K
- GSK$941
- Regeneron Healthcare Solutions, Inc.$733
- Mylan Specialty L.p.$586
- plus $2K from 25 others
What the payments were for
- Food & beverage$9,20596%
- Education$3614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 111 | $2,406 |
| Grifols USA, LLC | 71 | $1,367 |
| Boehringer Ingelheim | 62 | $1,274 |
| GSK | 56 | $941 |
| Regeneron Healthcare Solutions, Inc. | 40 | $733 |
| Mylan Specialty L.p. | 32 | $586 |
| Sanofi | 28 | $431 |
| Jazz Pharmaceuticals Inc. | 11 | $265 |
| Sanofi-aventis U.S. LLC | 3 | $238 |
| Viatris Specialty LLC | 12 | $183 |
| Actelion Pharmaceuticals US, Inc. | 7 | $169 |
| Axsome Therapeutics, Inc. | 2 | $102 |
| Merck | 5 | $86 |
| Avadel CNS Pharmaceuticals, LLC | 4 | $84 |
| Philips North America LLC | 5 | $83 |
| Bayer | 4 | $81 |
| Verona Pharma, Inc. | 4 | $81 |
| Harmony Biosciences LLC | 2 | $61 |
| Amgen | 3 | $59 |
| United Therapeutics Corporation | 3 | $52 |
| Insmed, Inc. | 3 | $50 |
| Resmed Corp | 2 | $42 |
| 3b Medical, Inc. | 1 | $39 |
| Phadia US Inc. | 2 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Covis Pharma GmbH | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,566 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 404 | $372,386 |
| OfevNintedanib Esylate | 22 | $277,364 |
| Breo ElliptaFluticasone/Vilanterol | 188 | $104,539 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 102 | $86,111 |
| Fasenra PenBenralizumab | 12 | $68,404 |
| Spiriva RespimatTiotropium Bromide | 95 | $64,794 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 102 | $62,219 |
| TezspireTezepelumab-Ekko | 11 | $51,025 |
| Advair HfaFluticasone Propion/Salmeterol | 58 | $26,461 |
| SymbicortBudesonide/Formoterol Fumarate | 69 | $23,656 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $23,165 |
| Qvar RedihalerBeclomethasone Dipropionate | 31 | $17,115 |
| DuleraMometasone/Formoterol | 25 | $16,697 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 49 | $15,914 |
| Tiotropium Bromide | 22 | $14,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $941 | $514,808660 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,274 | $404,377219 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Pulmicort Flexhaler | $2,406 | $167,671198 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $13 | $17,11531 claims |
| MerckDulera | $86 | $16,69725 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Lansing
- Lauren KaylorLansing$23K
- Kevin DuffyLansing$23K
- Antonio GiannelliLansing$22K
- Timothy PalmerLansing$17K
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.